Masson Rahul, Park Sarah, Shi Vivian Y, Hsiao Jennifer L, Aleshin Maria A
Keck School of Medicine of USC, University of Southern CA, Los Angeles, CA, USA.
David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Skin Appendage Disord. 2024 Jun;10(3):224-228. doi: 10.1159/000536094. Epub 2024 Jan 24.
Hidradenitis suppurativa (HS) is a chronic skin condition with recurrent, debilitating flares. Although the majority of patients with HS endorse flares, there is a lack of research regarding HS experts' flare management practices and perspectives.
An anonymous online survey was distributed through an HS expert listserv. Board-certified dermatologists who saw 1 or more HS patient(s) per month were eligible for participation.
A total of 35 responses were collected; 97.1% self-identified as HS experts. Therapies used for HS flares by more than two-thirds of the respondents included systemic antibiotics (100%), nonprescription pain relievers (91.4%), intralesional triamcinolone injections (91.4%), prescription pain relievers (71.4%), oral corticosteroids (68.6%), and warm compresses (68.6%). The top 3 dermatologist-reported barriers that patients face in accessing care during flares include lack of clinic appointment availability (88.6%), distance that patients have to travel to reach clinic (85.7%), and lack of transportation for patients (62.9%).
Overall, this study highlights variations in the ways that HS experts manage flares. Many of the treatment modalities used by the majority of respondents are not part of the official North American guidelines. Further prospective studies and expert consensus guidelines are needed to standardize the approach to flare management.
化脓性汗腺炎（HS）是一种慢性皮肤病，会反复发作，令人虚弱。尽管大多数HS患者都认可病情会发作，但对于HS专家在发作管理方面的做法和观点，缺乏相关研究。
通过HS专家邮件列表分发了一份匿名在线调查问卷。每月诊治1名或更多HS患者的皮肤科专科医生有资格参与。
共收集到35份回复；97.1%的人自认为是HS专家。超过三分之二的受访者用于HS发作的治疗方法包括全身性抗生素（100%）、非处方止痛药（91.4%）、病灶内注射曲安奈德（91.4%）、处方止痛药（71.4%）、口服糖皮质激素（68.6%）和热敷（68.6%）。皮肤科医生报告的患者在发作期间获得护理时面临的三大障碍包括缺乏门诊预约（88.6%）、患者前往诊所的路程（85.7%）以及患者缺乏交通工具（62.9%）。
总体而言，本研究突出了HS专家管理发作方式的差异。大多数受访者使用的许多治疗方式并非北美官方指南的一部分。需要进一步的前瞻性研究和专家共识指南来规范发作管理方法。
